Pediatric Antiphospholipid Syndrome

Current Rheumatology Reports

Volumn 17, Issue 4, 2015, Pages

  Aguiar, Cassyanne L ^a   Soybilgic, Arzu ^b   Avcin, Tadej ^c,d   Myones, Barry L ^e  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e Pediatric Rheumatology   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Neonatal; Pediatric; Thrombotic risk; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A INHIBITOR; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB; STEROID; THROMBIN INHIBITOR;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CHILDHOOD DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FETUS OUTCOME; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HUMAN; KIDNEY DISEASE; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS (TOPIC); NEUROLOGIC DISEASE; ONSET AGE; PLASMAPHERESIS; PRIMARY PREVENTION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEX RATIO; SOLID TUMOR; TERMINAL DISEASE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; VALVULAR HEART DISEASE; VERTICAL TRANSMISSION; AGE; CHILD; MEDICAL RESEARCH; NEWBORN; PROCEDURES; TRENDS;

AGE FACTORS; ANTIPHOSPHOLIPID SYNDROME; BIOMEDICAL RESEARCH; CHILD; HUMANS; INFANT, NEWBORN; RISK FACTORS;

EID: 84927603697     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0504-5     Document Type: Review

References (131)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
2. Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001;40(5):565–73.
3. Berkun Y, Simchen M, Strauss T, et al. Antiphospholipid antibodies in neonates with stroke–a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986–93.
4. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9(3):212–8.
5. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46(2):545–52.
6. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus. 1998;7 Suppl 2:S52–4.
7. Gharavi AE, Vega-Ostertag M, Espinola RG, et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus. 2004;13(1):17–23.
8. Wenzel C, Stoiser B, Locker G, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763–70.
9. Cruz-Tapias P, Blank M, Anaya JM, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.
10. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711–4.
11. Andreoli L, Nalli C, Motta M, et al. Anti-B2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis. 2011;70(2):380–3.
12. Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013;22(7):702–11.
13. Guerin J, Casey E, Feighery C, et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31(2):109–16.
14. Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-Beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18(11):1011–4.
15. Samarkos M, Davies K, Gordon C, et al. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25(2):199–204.
16. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.
17. Erkan D, Lockshin M. High risk antiphospholipid antibody profile: matter of the number or titer of tests? E-letter to the editor (re: Incidence of first thrombembolic event in asymptomatic carries of high-risk aPL profile: a multicenter prospective study, Pengo et al. Blood 2011;17:4714). Published online on 24 January 2012, available at: http://bloodjournal.hematologylibrary.org/letters.
18. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.
19. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5(5):925–30.
20. Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94.
21. Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatol Med. 2006;11(3):198–206.
22. Male C, Lechner K, Eichinger S, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134(2):199–205.
23. Flanders MM, Crist RA, Roberts WL, et al. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51(9):1738–42.
24. Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7. Most comprehensive descriptive characteristics of pediatric APS from an international registry.
25. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci. 2005;1051:465–86.
26. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74(1):415–25.
27. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–7.
28. Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein 1 antibodies in infants born to mother with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol. 2006;23(4):247–51.
29. Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.
30. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.
31. Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford). 2001;40(9):1026–32.
32. Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclases. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40(11):1998–2006.
33. Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus. 2007;16(8):634–41.
34. Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res. 2014;2014:672603.
35. Boffa MC, Aurousseau MH, Lachassinne E, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13(9):713–7.
36. Boffa MC, Lachassinne E, Boinot C, et al. European registry of babies born to mothers with antiphospholipid syndrome: a result update. Lupus. 2009;18(10):900–4.
37. Mekinian A, Carbillon L, Nicaise-Roland P, et al. Mothers’ antiphospholipid antibodies during pregnancy and the relation to offspring outcome. Clin Exp Rheumatol. 2014;32(3):446.
38. Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217–22. A prospective study aiming to describe the long-term outcomes of children born to mothers with antiphospholipid syndrome.
39. Nalli C, Iodice A, Andreoli L, et al. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus. 2014;23(6):507–17.
40. Ross G, Sammaritano L, Nass R, et al. Affects of mother’s autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157(4):397–402.
41. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med. 1999;27(3):183–7.
42. Nacinovich R, Galli J, Bomba M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum. 2008;59(3):345–51.
43. Abisror N, Mekinian A, Lachassinne E, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;43(3):348–51.
44. Gordon O, Almagor Y, Fridler D, et al. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 2014;44(2):241–5. A recent review of de novo neonatal APS.
45. Hansen K, Kong D, Moore K, et al. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001;28(9):2018–24.
46. Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothromboitc risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30(11):2385–91.
47. Rosendaal F, Siscovick D, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89(8):2817–21.
48. Giron-Gonzalez J, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560–7.
49. Kaul M, Erkan D, Sammaritano L, et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927–30.
50. Tolbert J, Carpenter SL. Common acquired causes of thrombosis in children. Curr Probl Pediatr Adolesc Health Care. 2013;43(7):169–77.
51. Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9.
52. Albisetti M, Moeller A, Waldvogel K, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol. 2007;117(3):149–55.
53. Revel-Vilk S, Chan A, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1(5):915–21.
54. Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am. 2013;60(6):1443–62.
55. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011;37(7):802–9. A meta-analysis describing the impact of antiphospholipid antibodies on the risk of thrombotic events in children.
56. Manco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol. 1995;48(4):240–3.
57. Tavil B, Ozyurek E, Gumruk F, et al. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347–52.
58. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19(4):406–11.
59. Lampropoulos CE, Koutroumanidis M, Reynolds PP, et al. Electroencephalography in the assessment of neuropsychiatric manifestation in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.
60. Biernacka-Zielinska M, Lipinska J, Szymanska-Kaluza J, et al. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report. J Med Case Rep. 2013;7:221.
61. Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23:1449–51.
62. Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):206–13.
63. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.
64. von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002;47(4):414–20.
65. Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia. 2002;43(1):52–9.
66. Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit. 2009;15(4):CR164–9.
67. Avčin T, Markelj G, Nikšič V, et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia. 2004;24(10):831–7.
68. Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes’) syndrome: changing the face of neurology. Eur J Intern Med. 2004;15(3):147–50.
69. Careaga M, Hansen RL, Hertz-Piccotto I, et al. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.
70. Zamora-Ustaran A, Escarcega-Alarcón RO, Garcia-Carrasco M, et al. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J. 2012;14(5):286–9.
71. Mazodier K, Arnaud L, Mathian A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):251–60.
72. Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850–5.
73. Garcia-Carrasco M, Galarza C, Gómez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus. 2007;16(5):366–73.
74. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.
75. Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003;12(6):449–53.
76. Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.
77. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16(8):627–33.
78. Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997;6(6):556–7.
79. Caporali R, Ravelli A, Ramenghi B, et al. Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. Arch Dis Child. 1992;67(11):1384–5.
80. Abend NS, Licht DJ, Spencer CH. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatr Neurol. 2007;36(5):345–7.
81. Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated henoch-Schonlein purpura. Arch Dis Child. 2002;86(2):132–3.
82. Meglic A, Grosek S, Benedik-Dolnicar M, et al. Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus. 2008;17(9):842–5.
83. Sherer Y, Livneh A, Levy Y, et al. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome: a novel overlap syndrome. Lupus. 2000;9(1):42–6.
84. Fung VS, Yiannikas C, Sue CM, et al. Is Sydenham’s chorea an antiphospholipid syndrome? J Clin Neurosci. 1998;5(1):115–8.
85. Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as a presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics. 1999;30(2):96–8.
86. Caporali R, Ravelli A, De Gennaro F, et al. Prevalence of anticardiolipin antibodies in juvenile arthritis. Ann Rheum Dis. 1991;50(9):599–601.
87. Southwood TR, Roberts-Thomson PJ, Ahern MJ, et al. Autoantibodies in patients with juvenile chronic arthritis and their immediate family relatives. Ann Rheum Dis. 1990;49(12):968–72.
88. Gedalia A, Molina IF, Garcia CO, et al. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus. 1998;7(8):551–3.
89. Rožiĝ M, Trampuš-Bakija A, Rener-Primec Z, et al. Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies. Arthritis Rheum. 2008;58:S711–2.
90. Avcin T, Cimaz R, Meroni PL. Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in paediatric population? Lupus. 2001;10(12):897–8.
91. Cabiedes J, Trejo-Hernandez J, Loredo-Abdala A, et al. Anti-cardiolipin, anticardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population. Arch Med Res. 2002;33(2):175–9.
92. Vaarala O, Palosuo T, Kleemola M, et al. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41(1):8–15.
93. Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005;210(10):799–805.
94. Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005;142(2):377–80.
95. Toplak N, Kveder T, Trampuš-Bakija A, et al. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. 2008;8(2):134–8.
96. Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal. 2000;14(3):87–90.
97. Siemens HJ, Gutsche S, Brückner S, et al. Antiphospholipid antibodies in children without and in adults with and without thrombophilia. Thromb Res. 2000;98(4):241–7.
98. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus. 2002;11(1):4–10.
99. Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):553–73.
100. Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523.
101. Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome. J Pediatr. 1997;130(6):998–1000.
102. Lee MT, Nardi MA, Hadzi-Nesic J, et al. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1½-year-old girl: report of a case and review of the literature. Am J Hematol. 1996;51(4):307–14.
103. Yacobovich JR, Uziel Y, Friedman Z, et al. Diffuse muscular haemorrhage as presenting sign of juvenile systemic lupus erythematosus and lupus anticoagulant hypoprothrombinaemia syndrome. Rheumatology (Oxford). 2001;40(5):585–7.
104. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8.
105. Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol. 2004;26(5):327–30.
106. Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322–32.
107. Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008;34(3):282–5.
108. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4.
109. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64(8):1205–9.
110. Manco-Johnson M, Wang M, Goldenberg N, et al. Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J Pediatr. 2012;161(4):682–8.
111. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):74–9.
112. Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnosis a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5(6):305–14. A review article summarizing the diagnostic challenges and recently updated diagnostic algorithms for CAPS.
113. Berman H, Rodríguez-Pintó I, Cervera R, et al. Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014;13(2):157–62. A descriptive analysis of pediatric patients from the CAPS registry.
114. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12(7):499–503.
115. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.
116. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.
117. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467–73.
118. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192–200.
119. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8.
120. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509.
121. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6(2):98–103.
122. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):70–6.
123. Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer. 2009;52(4):536–8.
124. Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics. 2010;125(6):e1523–8.
125. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12(11):1085–90. A descriptive analysis of the use of rituximab in pediatric CAPS.
126. Erkan D, Aguiar CL, Andrade D, et al. 14th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. A comprehensive review of the various treatments being used and studied for APS.
127. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185–90.
128. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.
129. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84. This is a prospective cohort study within the Warfarin versus Aspirin Recurrent Stroke Study (WARSS) [126] that specified in advance APS-related data and sample collection parameters and could be a model for future studies.
130. Liu X-W, Pierangeli SS, Barker J, et al. RBC adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin. Ann N Y Acad Sci. 1998;850:391–3.
131. Westerman M, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–62.